Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than 140 invention disclosures and 60 patent families.

The Illumina MiSeq i100 Series, announced last fall, is the company's first customer-installable instrument since the iSeq. Illumina's latest offering was a brand-new challenge for Staff Software ...

European shares edged higher in a choppy day of trading on Tuesday, as investors shifted their focus to quarterly earnings reports from companies such as UBS, BNP Paribas and Ferrari among others, ...

Buying $100 In ILMN: If an investor had bought $100 of ILMN stock 20 years ago, it would be worth $2,447.88 today based on a ...

BofA lowered the firm’s price target on Illumina (ILMN) to $90 from $110 and keeps an Underperform rating on the shares. Shares have fallen 25% ...

Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

Barclays downgraded Illumina (ILMN) to Underweight from Equal Weight with a price target of $100, down from $130. The firm sees greater risk to ...

(RTTNews) - Below are the earnings highlights for Illumina Inc. (ILMN): Earnings: $187 million in Q4 vs. -$176 million in the same period last year. EPS: $1.17 in Q4 vs. -$1.11 in the same period ...

Shares of Illumina (NASDAQ: ILMN) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m. ET. At that time ...

Illumina recently launched the MiSeq i100 and ... today announced the results of the annual reconstitution of the Nasdaq-100 Index® (Nasdaq: NDX®), which will become effective prior to market ...